Copy Link Print Information

RO8191

(Synonyms: CDM-3008; RO4948191)
24 Cited Publications
Customer Review

Based on 24 publication(s) in Google Scholar

RO8191 (CDM-3008), an imidazonaphthyridine compound, is an orally active and potent interferon (IFN) receptor agonist. RO8191 directly binds to IFNα/β receptor 2 (IFNAR2) and activates IFN-stimulated genes (ISGs) expression and JAK/STAT phosphorylation. RO8191 shows antiviral activity against both HCV and EMCV with an IC50 of 200 nM for HCV replicon. RO8191 is a cccDNA modulator (CDM) through interferon-like activity and has anti-HBV activity.

For research use only. We do not sell to patients.

  • Purity: 98.80%
  • CAS No.: 691868-88-9
  • Formula: C14H5F6N5O
  • Molecular Weight:373.21
  • Storage:

    -20°C, stored under nitrogen

    * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

  • RO8191 Chemical Structure
    RO8191 Chemical Structure
  • Experimental Validation Results for RO8191
  • Experimental Validation Results for RO8191
  • Experimental Validation Results for RO8191
  • Experimental Validation Results for RO8191
  • Experimental Validation Results for RO8191
  • Experimental Validation Results for RO8191
CAS No.: 691868-88-9
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Purity & Documentation
  • References
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) RO8191

More
Customer Validation & Images
WBBio/Physico-chemical AssayHistological Imaging/StainingIFFlow Cytometry
  • WB
  • IF
  • Flow Cytometry
  • Histological Imaging/Staining
  • Histological Imaging/Staining
  • Bio/Physico-chemical Assay

All JAK Isoforms

More

All STAT Isoforms

More
Keywords
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • RO8191 Chemical Structure
    RO8191 Chemical Structure
    1/16
  • 1/16

    RO8191 purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Jun:141:156660. [Abstract]

    Customer Validation
     Protein expression and phosphorylation of CD4+ T cells treated with BSA, OA or OA+RO8191 (20 μM; 3 days) assessed by western blotting (n = 3 per group). The results showed that addition of RO8191 to OA-treated CD4+ T cells significantly reversed the down-regulation of pSTAT5A (Y694) as well as inhibition of IL-10 expression.

  • 1/16

    RO8191 purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Jun:141:156660. [Abstract]

    Customer Validation
     Representative images of p-STAT5A (Y694) in CD4+ T cells treated with OA or OA + RO8191 (20 μM; 3 days), with quantification of p-STAT5A (Y694). Immunofluorescence showed that the nucleus localization of pSTAT5A was enhanced after addition of RO8191 in OA-treated CD4+ T cells. scale bar, 20 μm.

  • 1/16

    RO8191 purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Jun:141:156660. [Abstract]

    Customer Validation
     Flow cytometry analysis of the percentage of Th1, Th17 and Treg cells in CD4+ T cells treated with BSA, OA, or OA+. NS, non-significance. RO8191 (20 μM; 3 days) reversed the up-regulation of Th17 and suppression of Treg cell proportion, but not the promotion of Th1 cell frequency in OA-treated CD4+ T cells.

  • 1/16

    RO8191 purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2024 Jul 28;10(1):341. [Abstract]

    Customer Validation
     RO8191 (30 mg/kg; p.o.; once daily for 14 days). Representative haematoxylin and eosin (H&E) sections of tracheal allografts harvested on day 28 (left panel) and corresponding statistical diagram (right panel) showing the degree of stenosis.

  • 1/16

    RO8191 purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2024 Jul 28;10(1):341. [Abstract]

    Customer Validation
     RO8191 (30 mg/kg; p.o.; once daily for 14 days). Representative Masson staining sections of the transplanted trachea (left panel) and corresponding statistical charts (right panel) illustrating collagen deposition.

  • 1/16

    RO8191 purchased from MedChemExpress. Usage Cited in: Cancer Immunol Res. 2023 May 3;11(5):583-599. [Abstract]

    Customer Validation
     ISG-THP1 (WT) or ISG-THP1 (STING KO) cells were treated with cGAMP (0.5 μM), or RO8191 (2.5 μM) with or without various doses of podofilox for 24 h. Normalized values for ISRE luciferase activity induced by cGAMP (or RO8191) along with podofilox are shown in comparison to the activity triggered by DMSO. The results showed that podofilox only showed a tendency to enhance the ISRE-driven immune response when stimulated with RO8191, which is an agonist that directly binds to IFNAR2 and activates the expression of ISGs.

  • RO8191